Answers are grounded in this paper and cite their sources.
Case-series report details skin toxicity management in NRAS-mutant melanoma, suggesting effective interventions.
Abstract Introduction Naporafenib (LXH254) is an orally bioavailable, type II RAF inhibitor that inhibits both BRAF and CRAF, thereby reducing paradoxical activation and inhibiting the mitogen-activated protein kinase (MAPK) signaling. A phase I and II study showed promising results in the treatment of neuroblastoma and NRAS-mutant melanoma. However, naporafenib-related skin toxicities such as rash and acneiform dermatitis appeared in 35 % and 28 % of treated patients, respectively. As acneiform eruptions can significantly affect patients' quality of life and lead to dose-reduction or discontinuation, appropriate diagnostics, and management of cutaneous adverse events, including prophylactic and supportive measures, are essential. Patients and methods In order to deepen the knowledge regarding cutaneous side effects of RAF inhibitors we present a case-series of five patients treated with naporafenib for metastatic melanoma who developed drug-related papulo-pustular rash. Results Analyzing the individual skin-related toxicities, histopathological findings, the impact of skin toxicity on cancer treatment and the different management strategies, our findings indicate that intensive prophylactic measures and early detection are as crucial as specific diagnostics for a rapid control of skin toxicity associated with naporafenib. Conclusion Additional preemptive measures as systemic doxycycline, tapered after the first weeks may be one possible approach to impede dose reduction or interruption of naporafenib.
No takes yet. Share an insight, caveat, or question.
Hoheisel et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: